N L Edwards, M.D.
PROF & PRG DIR
Accomplishments
Master of the American College of Physicians
2015
·
American College of Physicians
Master of the American College of Rheumatology
2015
·
American College of Rheumatology
Teaching Profile
Courses Taught
2018
MDC7200 Medicine Clerkship
2018
MDC7203 Senior Medicine Clerk
2021
PAS5020 Intro to Medicine 2
Board Certifications
-
Internal MedicineAmerican Board of Internal Medicine
-
RheumatologyAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Rheumatology
Areas of Interest
- Gout
- Granulomatosis with polyangiitis
- Osteoarthritis
- Rheumatoid arthritis
Publications
2023
Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set.
Seminars in arthritis and rheumatism.
60
[DOI] 10.1016/j.semarthrit.2023.152191.
[PMID] 36963128.
2022
Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.
Current rheumatology reports.
24(1):12-19
[DOI] 10.1007/s11926-022-01055-9.
[PMID] 35167037.
2022
Gout management and outcomes during established COVID-19 pandemic in 2020-2021: a cross-sectional Internet survey.
Therapeutic advances in musculoskeletal disease.
14
[DOI] 10.1177/1759720X221096381.
[PMID] 35586516.
2021
Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
Clinical and experimental rheumatology.
39(5):1085-1092
[DOI] 10.55563/clinexprheumatol/b7jjnb.
[PMID] 33427618.
2021
Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group.
Seminars in arthritis and rheumatism.
51(4):946-950
[DOI] 10.1016/j.semarthrit.2021.04.019.
[PMID] 34140183.
2020
Development of a multivariable improvement measure for gout.
Arthritis research & therapy.
22(1)
[DOI] 10.1186/s13075-020-02254-4.
[PMID] 32600452.
2020
Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey.
Therapeutic advances in musculoskeletal disease.
12
[DOI] 10.1177/1759720X20966124.
[PMID] 33133248.
2020
Management of Gout in the United States: A Claims-based Analysis.
ACR open rheumatology.
2(3):180-187
[DOI] 10.1002/acr2.11121.
[PMID] 32114719.
2020
Patient Perceptions of Gout Management Goals: A Cross-sectional Internet Survey.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
26(4):129-133
[DOI] 10.1097/RHU.0000000000000981.
[PMID] 32453285.
2020
Response to the 2020 American College of Rheumatology Guideline for the Management of Gout: Comment on the Article by FitzGerald et al.
Arthritis care & research.
72(10):1506-1507
[DOI] 10.1002/acr.24379.
[PMID] 32702211.
2019
Evaluation of Proposed Criteria for Remission and Evidence-Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout.
ACR open rheumatology.
1(4):236-243
[DOI] 10.1002/acr2.1025.
[PMID] 31777799.
2019
Experience of finding footwear and factors contributing to footwear choice in people with gout: a mixed methods study using a web-based survey.
Journal of foot and ankle research.
12
[DOI] 10.1186/s13047-018-0313-y.
[PMID] 30636975.
2019
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.
Annals of the rheumatic diseases.
78(11):1592-1600
[DOI] 10.1136/annrheumdis-2019-215933.
[PMID] 31501138.
2019
Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.
Arthritis care & research.
71(3):427-434
[DOI] 10.1002/acr.23607.
[PMID] 29799677.
2018
EULAR gout treatment guidelines by Richette et al.: uric acid and neurocognition.
Annals of the rheumatic diseases.
77(4)
[DOI] 10.1136/annrheumdis-2017-211418.
[PMID] 28347993.
2017
Renal dosing of allopurinol results in suboptimal gout care.
Annals of the rheumatic diseases.
76(1)
[DOI] 10.1136/annrheumdis-2016-210352.
[PMID] 27582422.
2016
A cross-sectional internet-based patient survey of the management strategies for gout.
BMC complementary and alternative medicine.
16
[DOI] 10.1186/s12906-016-1067-3.
[PMID] 26931313.
2016
Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?
Postgraduate medicine.
128(7):706-15
[DOI] 10.1080/00325481.2016.1221732.
[PMID] 27558643.
2015
2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Arthritis & rheumatology (Hoboken, N.J.).
67(10):2557-68
[DOI] 10.1002/art.39254.
[PMID] 26352873.
2015
2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Annals of the rheumatic diseases.
74(10):1789-98
[DOI] 10.1136/annrheumdis-2015-208237.
[PMID] 26359487.
2015
An internet survey of common treatments used by patients with gout including cherry extract and juice and other dietary supplements.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
21(4):225-6
[DOI] 10.1097/RHU.0000000000000246.
[PMID] 26010189.
2014
Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout.
The Journal of rheumatology.
41(3):574-80
[DOI] 10.3899/jrheum.131245.
[PMID] 24429178.
2014
Emerging therapies for gout.
Rheumatic diseases clinics of North America.
40(2):375-87
[DOI] 10.1016/j.rdc.2014.01.013.
[PMID] 24703353.
2014
OMERACT endorsement of measures of outcome for studies of acute gout.
The Journal of rheumatology.
41(3):569-73
[DOI] 10.3899/jrheum.131246.
[PMID] 24334651.
2013
A delphi exercise to identify characteristic features of gout – opinions from patients and physicians, the first stage in developing new classification criteria.
The Journal of rheumatology.
40(4):498-505
[DOI] 10.3899/jrheum.121037.
[PMID] 23418379.
2012
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.
Arthritis care & research.
64(10):1431-46
[DOI] 10.1002/acr.21772.
[PMID] 23024028.
2012
2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.
Arthritis care & research.
64(10):1447-61
[DOI] 10.1002/acr.21773.
[PMID] 23024029.
2012
Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
The Journal of rheumatology.
39(7):1450-7
[DOI] 10.3899/jrheum.111375.
[PMID] 22660805.
2011
2011 recommendations for the diagnosis and management of gout and hyperuricemia.
The Physician and sportsmedicine.
39(4):98-123
[DOI] 10.3810/psm.2011.11.1946.
[PMID] 22293773.
2011
2011 Recommendations for the diagnosis and management of gout and hyperuricemia.
Postgraduate medicine.
123(6 Suppl 1):3-36
[DOI] 10.3810/pgm.2011.11.2511.
[PMID] 22156509.
2011
Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials.
The Journal of rheumatology.
38(7):1467-70
[DOI] 10.3899/jrheum.110274.
[PMID] 21724718.
2011
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
JAMA.
306(7):711-20
[DOI] 10.1001/jama.2011.1169.
[PMID] 21846852.
2011
Patient-reported outcomes in chronic gout: a report from OMERACT 10.
The Journal of rheumatology.
38(7):1452-7
[DOI] 10.3899/jrheum.110271.
[PMID] 21724715.
2011
Quality of care in patients with gout: why is management suboptimal and what can be done about it?
Current rheumatology reports.
13(2):154-9
[DOI] 10.1007/s11926-010-0154-6.
[PMID] 21161617.
2011
Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers.
Seminars in arthritis and rheumatism.
40(6):483-500
[DOI] 10.1016/j.semarthrit.2010.09.003.
[PMID] 21056459.
2011
Serum urate in chronic gout–will it be the first validated soluble biomarker in rheumatology?
The Journal of rheumatology.
38(7):1462-6
[DOI] 10.3899/jrheum.110273.
[PMID] 21724717.
2011
Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities.
The Journal of rheumatology.
38(7):1458-61
[DOI] 10.3899/jrheum.110272.
[PMID] 21724716.
2011
Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy.
Journal of medical economics.
14(1):10-5
[DOI] 10.3111/13696998.2010.540874.
[PMID] 21138339.
2010
Chronic Gout: Epidemiology, Disease Progression, Treatment and Disease Burden
Current Medical Research and Opinion.
26(12):2813-2821
[DOI] 10.1185/03007995.2010.533647.
[PMID] 21050059.
2010
Managing gout in the primary care setting: what you and your patients need to know.
The American journal of medicine.
123(8)
[DOI] 10.1016/j.amjmed.2010.06.005.
[PMID] 20670699.
2010
Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion.
Cleveland Clinic journal of medicine.
77 Suppl 2:S2-25
[DOI] 10.3949/ccjm.77.s2.01.
[PMID] 20516241.
2009
Febuxostat: a new treatment for hyperuricaemia in gout.
Rheumatology (Oxford, England).
48 Suppl 2:ii15-ii19
[DOI] 10.1093/rheumatology/kep088.
[PMID] 19447778.
2009
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
Arthritis research & therapy.
11(4)
[DOI] 10.1186/ar2761.
[PMID] 19725932.
2009
Outcome Domains for Studies of Acute and Chronic Gout
The Journal of rheumatology.
36(10):2342-2345
[DOI] 10.3899/jrheum.090370.
[PMID] 19820223.
2009
Progress in measurement instruments for acute and chronic gout studies.
The Journal of rheumatology.
36(10):2346-55
[DOI] 10.3899/jrheum.090371.
[PMID] 19820224.
2009
The role of hyperuricemia in vascular disorders.
Current opinion in rheumatology.
21(2):132-7
[DOI] 10.1097/BOR.0b013e3283257b96.
[PMID] 19339923.
2008
Clinical Homogeneity and Syndromic Characteristics of Treatment Failure Gout (Tfg) in Four Independent Cohorts
Arthritis and Rheumatism.
58:S180-S181
2008
Efficacy and Safety of Intravenous (Iv) Pegloticase (Pgl) in Subjects With Treatment Failure Gout (Tfg): Phase 3 Results From Gout1 and Gout2
Arthritis and Rheumatism.
58:S400-S401
2008
Febuxostat – a Viewpoint
Annals of epidemiology.
68(2):1875-1876
[DOI] 10.2165/00003495-200868130-00007.
[PMID] 24342030.
2008
Febuxostat : a viewpoint by N. Lawrence Edwards.
Drugs.
68(13):1875-6
[PMID] 18729540.
2008
Health-Related Quality-Of-Life (Hrqol) of Patients With Refractory Gout (Refractory-Gout) and Us Veterans Administration Patients With Gout and Comorbities (Va-Gout) Is Poor and Comparable To That in Other Severe Chronic Conditions
Arthritis and Rheumatism.
58
2008
Immunoreactivity and Clinical Response To Pegloticase (Pgl): Pooled Data From Gout1 and Gout2, Pgl Phase 3 Randomized, Double Blind, Placebo-Controlled Trials
Arthritis and Rheumatism.
58
2008
Immunoreactivity and Clinical Response To Pegloticase (Pgl): Pooled Data From Gout1 and Gout2, Pgl Phase 3 Randomized, Double Blind, Placebo-Controlled Trials
Arthritis and Rheumatism.
58
2008
Improvement in Health-Related Quality of Life (Hrql) and Disability Index in Treatment Failure Gout (Tfg) After Pegloticase (Pgl) Therapy: Pooled Results From Gout1 and Gout2, Phase 3, Randomized Double Blind, Placebo (Pbo)-Controlled Trials
Arthritis and Rheumatism.
58
2008
In defense of research into the crystal induced arthropathies.
The Journal of rheumatology.
35(11):2278-9; author reply 2279
[DOI] 10.3899/jrheum.080599.
[PMID] 19004057.
2008
The role of hyperuricemia and gout in kidney and cardiovascular disease.
Cleveland Clinic journal of medicine.
75 Suppl 5:S13-6
[PMID] 18822470.
2008
Tophus Response To Pegloticase (Pgl) Therapy: Pooled Results From Gout1 and Gout2, Pgl Phase 3 Randomized, Double Blind, Placebo-Controlled Trials
Arthritis and Rheumatism.
58
2008
Treatment-failure gout: a moving target.
Arthritis and rheumatism.
58(9):2587-90
[DOI] 10.1002/art.23803.
[PMID] 18759307.
2008
Work Productivity Loss Due To Flares in Treatment-Failure Gout (Tfg)
Arthritis and Rheumatism.
58
2007
Outcome evaluations in gout.
The Journal of rheumatology.
34(6):1381-5
[PMID] 17552064.
2006
Case 6: maintenance therapy for simple intermittent gout.
The American journal of medicine.
119(11 Suppl 1):S20-2
[PMID] 17059908.
2006
Case 7: differential diagnosis of advanced gout.
The American journal of medicine.
119(11 Suppl 1):S23-4
[PMID] 17059909.
2006
Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency.
The American journal of medicine.
119(11 Suppl 1):S29-31
[PMID] 17059911.
2005
Treatment of osteoarthritis.
Southern medical journal.
98(2):205-9
[PMID] 15759951.
1996
Magnetic resonance imaging of tophaceous gout in the hands and wrists.
Seminars in arthritis and rheumatism.
25(4):282-9
[PMID] 8834016.
1995
Axial skeletal changes in paralysed patients may mimic ankylosing spondylitis.
British journal of rheumatology.
34(2):174-7
[PMID] 7704467.
1995
Clinical pathogenesis and diagnosis of osteoarthritis.
Contemporary internal medicine.
7(6):13-6, 21
[PMID] 10150438.
1995
New insights into gouty arthritis.
Contemporary internal medicine.
7(1):55-64
[PMID] 10150333.
1991
Drugs to lower uric acid levels. How to avoid misuse in gouty arthritis.
Postgraduate medicine.
89(2):111-3, 116
[PMID] 1990384.
1990
Magnetic resonance imaging in patients with inflammatory arthritis of the knee.
Clinical rheumatology.
9(1):73-83
[PMID] 2335054.
1989
Cerebrospinal fluid cyclic nucleotide alterations in the Lesch-Nyhan syndrome.
Advances in experimental medicine and biology.
253A:181-4
[PMID] 2560331.
1989
Metabolism of guanosine and its C-8 substituted analogues in human lymphocyte cytoplasm.
Advances in experimental medicine and biology.
253B:285-9
[PMID] 2610119.
1989
Profile of a meeting: how abstracts are written and reviewed.
The Journal of rheumatology.
16(2):145-7
[PMID] 2746562.
1988
‘Rhupus’ syndrome.
Archives of internal medicine.
148(7):1633-6
[PMID] 3382309.
1988
Vasculitis associated with malignancy. Experience with 13 patients and literature review.
Medicine.
67(4):220-30
[PMID] 3292873.
1987
Silicone and rheumatic diseases.
Seminars in arthritis and rheumatism.
17(2):112-8
[PMID] 3334283.
Education
Fellowship – Rheumatology
1979
·
University of Michigan
Residency – Internal Medicine
1976
·
Creighton University
Medical School
1973
·
University of Miami
Contact Details
Phones:
- Business:
- (352) 265-0239
Emails:
- Business:
- edwarnl@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100277
GAINESVILLE FL 32610 - Business Street:
-
J. HILLIS MILLER HEALTH CENTER ROOM 4102
J. HILLIS MILLER HEALTH CENTER
GAINESVILLE FL 326100001